HUP0400607A3 - Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases - Google Patents

Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases

Info

Publication number
HUP0400607A3
HUP0400607A3 HU0400607A HUP0400607A HUP0400607A3 HU P0400607 A3 HUP0400607 A3 HU P0400607A3 HU 0400607 A HU0400607 A HU 0400607A HU P0400607 A HUP0400607 A HU P0400607A HU P0400607 A3 HUP0400607 A3 HU P0400607A3
Authority
HU
Hungary
Prior art keywords
prophylaxis
cardiac
treatment
pharmaceutical composition
controlled release
Prior art date
Application number
HU0400607A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Sun Pharmaceutical Ind Ltd Mum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd Mum filed Critical Sun Pharmaceutical Ind Ltd Mum
Publication of HUP0400607A2 publication Critical patent/HUP0400607A2/hu
Publication of HUP0400607A3 publication Critical patent/HUP0400607A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Packaging Frangible Articles (AREA)
HU0400607A 2001-05-17 2002-05-10 Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases HUP0400607A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN464MU2001 IN191028B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2001-05-17 2001-05-17
PCT/IN2002/000118 WO2002092078A1 (en) 2001-05-17 2002-05-10 Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases

Publications (2)

Publication Number Publication Date
HUP0400607A2 HUP0400607A2 (hu) 2004-07-28
HUP0400607A3 true HUP0400607A3 (en) 2005-07-28

Family

ID=11097247

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400607A HUP0400607A3 (en) 2001-05-17 2002-05-10 Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases

Country Status (16)

Country Link
US (1) US20030035836A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP1395258A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2004534031A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20040037026A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1525855A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2002314515B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE1014328A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR0210976A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2447005A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUP0400607A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN191028B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA03010501A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL370589A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2003133446A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2002092078A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200309724B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3024399A (en) 1998-04-03 1999-10-25 Bm Research A/S Controlled release composition
DK1429734T3 (da) * 2001-09-21 2008-05-13 Egalet As Faste dispersioner af carvedilol til kontrolleret afgivelse
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
EP2957281A1 (en) 2001-09-21 2015-12-23 Egalet Ltd. Polymer release system
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
WO2003092622A2 (en) * 2002-04-30 2003-11-13 Sb Pharmco Puerto Rico Inc. Carvedilol monocitrate monohydrate
EP1539140A4 (en) 2002-06-27 2005-12-07 Sb Pharmco Inc CARVEDILOLHYDOBROMID
WO2004002419A2 (en) 2002-06-27 2004-01-08 Sb Pharmco Puerto Rico Inc. Carvedilol phosphate salts and/or solvates thereof, correspondinq compositions, and/or methods of treatment
WO2004041252A1 (en) * 2002-11-08 2004-05-21 Egalet A/S Controlled release carvedilol compositions
WO2004047837A2 (en) * 2002-11-22 2004-06-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-blockers having antioxidant and nitric oxide-donor activity
ATE495732T1 (de) 2003-03-26 2011-02-15 Egalet As Morphin-system mit kontrollierter freisetzung
ATE454886T1 (de) * 2003-03-26 2010-01-15 Egalet As Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen
EP1615626B1 (en) * 2003-04-24 2009-10-14 Jagotec Ag Tablet with coloured core
US7260685B2 (en) 2003-06-20 2007-08-21 Micron Technology, Inc. Memory hub and access method having internal prefetch buffers
TWI344363B (en) * 2003-09-12 2011-07-01 Amgen Inc Rapid dissolution formulation of a calcium receptor-active compound
US7120743B2 (en) 2003-10-20 2006-10-10 Micron Technology, Inc. Arbitration system and method for memory responses in a hub-based memory system
WO2005051325A2 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol compositions methods of treatment and delivery
EP1686986A4 (en) 2003-11-25 2009-05-27 Sb Pharmco Inc CARVEDILOL SALTS, CORRESPONDING COMPOSITIONS, METHODS OF ADMINISTRATION AND / OR TREATMENT
ES2662903T3 (es) * 2003-11-25 2018-04-10 Smithkline Beecham (Cork) Limited Base libre de carvedilol, sales, formas anhidras o solvato de la misma, composiciones farmacéuticas correspondientes, formulaciones de liberación controlada, y procedimientos de tratamiento o administración
US20070196396A1 (en) * 2004-02-11 2007-08-23 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
AU2006254554B2 (en) * 2005-06-03 2011-11-24 Egalet Ltd A solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
WO2007144785A2 (en) * 2006-03-26 2007-12-21 Uti Limited Partnership Ryanodine receptor inhibitors and methods relating thereto
HRP20130148T4 (hr) 2006-08-03 2016-10-07 Horizon Pharma Ag Liječenje reumatske bolesti glukokortikoidima s odgođenim otpuštanjem
WO2008070072A2 (en) * 2006-12-01 2008-06-12 Mutual Pharmaceutical Company, Inc. Carvedilol forms, compositions, and methods of preparation thereof
US20090028935A1 (en) * 2006-12-01 2009-01-29 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
US20100291205A1 (en) * 2007-01-16 2010-11-18 Egalet A/S Pharmaceutical compositions and methods for mitigating risk of alcohol induced dose dumping or drug abuse
WO2008114276A1 (en) * 2007-03-16 2008-09-25 Lupin Limited Novel oral controlled release composition of carvedilol
BRPI0701904A2 (pt) * 2007-04-27 2008-12-09 Libbs Farmaceutica Ltda forma farmacÊutica de liberaÇço controlada de princÍpios ativos com solubilidade dependente do baixo ph do meio e processo para preparar a forma farmacÊutica
NZ580972A (en) 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
WO2010084188A1 (en) * 2009-01-26 2010-07-29 Nitec Pharma Ag Delayed-release glucocorticoid treatment of asthma
AU2010211220B2 (en) 2009-02-06 2013-08-01 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
NZ603579A (en) 2009-06-24 2014-02-28 Egalet Ltd Controlled release formulations
TWI415604B (zh) * 2009-09-29 2013-11-21 Tsh Biopharm Corp Ltd 調控釋放卡菲蒂羅劑型
JP5714562B2 (ja) * 2010-02-22 2015-05-07 第一三共株式会社 経口用徐放性固形製剤
EP2540318B1 (en) 2010-02-22 2018-10-24 Daiichi Sankyo Company, Limited Sustained-release solid preparation for oral use
CA2877183A1 (en) 2012-07-06 2014-01-09 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
KR102127625B1 (ko) 2012-09-03 2020-06-29 다이이찌 산쿄 가부시키가이샤 하이드로모르폰염산염 함유의 경구용 서방성 의약 조성물
KR102241487B1 (ko) 2013-02-20 2021-04-16 주식회사 종근당 제어방출 펠릿으로 된 약제학적 조성물
KR102158339B1 (ko) 2016-02-05 2020-09-21 삼진제약주식회사 인습성이 개선된 카르베딜롤 속방성 제제

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
JP2001514651A (ja) * 1997-03-11 2001-09-11 ダーウィン・ディスカバリー・リミテッド Ｒ−およびｓ−エナンチオマーの別の部分を含む製剤
IE970588A1 (en) * 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
US20020054911A1 (en) * 2000-05-11 2002-05-09 Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi Novel oral dosage form for carvedilol
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
JP2003514019A (ja) * 1999-11-15 2003-04-15 スミスクライン・ビーチャム・コーポレイション カルベジロールメタンスルホン酸塩
US6491949B2 (en) * 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
US6352721B1 (en) * 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
ES2227206T3 (es) * 2000-04-03 2005-04-01 F. Hoffmann-La Roche Ag Soluciones concentradas de carvedilol.
EP1335707A4 (en) * 2000-10-24 2005-07-06 Smithkline Beecham Corp NEW CARVEDILOL FORMULATIONS

Also Published As

Publication number Publication date
PL370589A1 (en) 2005-05-30
EP1395258A1 (en) 2004-03-10
JP2004534031A (ja) 2004-11-11
BE1014328A7 (fr) 2003-08-05
US20030035836A1 (en) 2003-02-20
HUP0400607A2 (hu) 2004-07-28
WO2002092078A1 (en) 2002-11-21
KR20040037026A (ko) 2004-05-04
IN191028B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2003-09-13
ZA200309724B (en) 2005-05-25
AU2002314515B2 (en) 2007-08-16
BR0210976A (pt) 2004-10-05
CN1525855A (zh) 2004-09-01
RU2003133446A (ru) 2005-03-10
CA2447005A1 (en) 2002-11-21
MXPA03010501A (es) 2004-03-02

Similar Documents

Publication Publication Date Title
HUP0400607A3 (en) Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases
HUP0203437A3 (en) Use of resorcinol derivatives for producing pharmaceutical compositions for treatment of immune diseases
EP1578421A4 (en) PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF DISEASES AND BREAST CONDITIONS
IL151689A0 (en) Intracorporeal medicaments for photodynamic treatment of disease
EP1404343A4 (en) THERAPEUTIC COMBINATIONS FOR THE TREATMENT OF HORMONE DEFICIENCIES
WO2004041067A3 (en) Prevention and treatment of synucleinopathic disease
HUP0302726A3 (en) Methods of administering pharmaceutical composition containing epothilone analogs for the treatment of cancer and of preparation the same
EP1558220A4 (en) ORAL COMPOSITIONS FOR THE TREATMENT OF DISEASES
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
AU2003278775A8 (en) Porifera-based therapeutic compositions for treating and preventing skin diseases
IL127943A0 (en) Pharmaceutical and cosmetic composition for the treatment of skin disorders
AU7434101A (en) Treatment of bone diseases
EP1560593A4 (en) NEW COMPOSITION AND METHOD FOR THE TREATMENT OF IMMUNE DISEASES
EP1536834A4 (en) DESIGN OF CHEMOKINE ANALOGS FOR THE TREATMENT OF HUMAN DISEASES
AU2002357830A8 (en) Methods and devices for therapeutic treatment cardiac and other pathologies
HUP0104963A3 (en) Compositions for the treatment of skin diseases
AU2003271021A8 (en) Immunogen for preparation of therapeutic vaccines or drugs for treatment of hepatitis b and the producing method and use thereof
HUP9904317A3 (en) Use of 1-hydroxy-2-pyridones for producing pharmaceutical compositions suitable for the treatment of skin diseases
HUP0401392A3 (en) Use of composition comprising anti-hla-antibody for treatment of diseases involving prolierative immune response
GB0004531D0 (en) The treatment of respiratory diseases
AU2002338303A1 (en) Therapeutic compositions for the treatment of a respiratory tract disease
AU2002325169A1 (en) Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases
EP1472273A4 (en) COMPOSITIONS AND METHODS FOR TREATING IMMUNE DISEASES
GB9908059D0 (en) Diagnosis and treatment of diseases
AU2908501A (en) Combination therapy for the treatment of inflammatory and respiratory diseases

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees